Cargando...
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...
Gardado en:
| Publicado en: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5119973/ https://ncbi.nlm.nih.gov/pubmed/27734608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.883 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|